Target description
Small cell cancer of the ovary hypercalcemic type (SCCOHT) is a rare form of highly aggressive cancer that primarily affects young women between the ages of 13 to 35. Very few cell lines or other models are currently available to study this devastating form of cancer. Although this cancer is often diagnosed at early stages, it has an especially poor prognosis with more than half of patients diagnosed with stage IA dying within two years. This type of cancer has been distinguished from other related malignancies including transitional cell carcinoma of the ovary, ovarian epithelial tumors, and ovarian germ cell tumors. Many other cell lines are available to study different ovarian carcinoma types, but no cellular model appears to exhibit the unique properties of SCCOHT-1. Biopsy material from a recurrent SCCOHT tumor was used for explant culturing. The new culture that became adherent and continued to proliferate was labeled “SCCOHT-1.” Characterization of the SCCOHT-1 cell line reveals an average diameter of 13 um and an estimated 36 hour doubling time. SCCOHT-1 cells are positive for CD29 and negative for CD24 and CD45 as assessed by flow cytometry. Injection of distinct subpopulations of the SCCOHT-1 cell line exhibited tumor development 100% of the time in NOD/SCID mice.1 Additionally, research groups have identified mutations resulting in loss of SMARCA4 protein which appears to be highly specific for SCCOHTs. SMARCA4 protein forms an important ATPase of the SWI/SNF chromatin remodeling complex which is also often implicated as a tumor suppressor. SCCOHT-1 cells provide a new tool to study the rare SCCOHT form of cancer and for the potential development of relevant therapeutic strategies in the future.Source:SCCOHT-1 cell line was created through explant culturing of a biopsied recurrent SCCOHT tumor taken from a 31-year old female patient.References: 1. Otte A, Göhring G, Steinemann D, Schlegelberger B, Groos S, Länger F, Kreipe H-H, Schambach A, Neumann T, Hillemanns P, et al. 2012. A tumor-derived population (SCCOHT-1) as cellular model for a small cell ovarian carcinoma of the hypercalcemic type. Int J Oncol. 41(2): 765-775.2. Karnezis AN, Wang Y, Ramos P, Hendricks WP, Oliva E, D′Angelo E, Prat J, Nucci MR, Nielsen TO, Chow C. 2016. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. J Pathol. 238(3): 389-400.
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.